COVID-Relief Bill Spares Generic Drug Makers

By John Wilkerson / December 23, 2020 at 1:09 PM
The coronavirus-relief bill does not include a measure, opposed by generic drug makers, that would have stopped them from blocking competitors by parking 180-day generic exclusivity periods. When the Association for Accessible Medicines learned that lawmakers were considering adding the Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act as an offset for coronavirus relief, the generic drug lobby sprang into action . BLOCKING has strong bipartisan support, and it’s backed by the White House. The...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.